Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol

详细信息    查看全文

• 作者：Diana Eccles (1)
  Sue Gerty (1)
  Peter Simmonds (1)
  Victoria Hammond (1)
  Sarah Ennis (1)
  Douglas G Altman (2)
  
• 刊名：BMC Cancer
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：7
• 期：1
• 全文大小：507KB
• 参考文献：1. Cancer Research UK [http://info.cancerresearchuk.org/cancerstats/types/breast/]
  2. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, / et al.: Women age < or = 35 years with primary breast carcinoma: disease features at presentation. / Cancer 2005, 103: 2466鈥?472. CrossRef
  3. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, / et al.: Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. / Ann Oncol 2006, 10: 1497鈥?503. CrossRef
  4. Euhus DM: Understanding mathematical models for breast cancer risk assessment and counseling. / Breast J 2001, 7: 224鈥?32. CrossRef
  5. Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for finding cancer-susceptibility genetic variants. / Nat Rev Cancer 2004, 4: 850鈥?60. CrossRef
  6. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, / et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. / Nat Genet 2007, 39: 165鈥?67. CrossRef
  7. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, / et al.: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. / Nat Genet 2006, 38: 873鈥?75. CrossRef
  8. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, / et al.: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. / Nat Genet 2006, 38: 1239鈥?241. CrossRef
  9. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, / et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. / Nature 2007.
  10. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, / et al.: Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. / Breast Cancer Res Treat 2005, 90: 5鈥?4. CrossRef
  11. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, / et al.: Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. / J Clin Oncol 2005, 23: 7503鈥?511. CrossRef
  12. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van d V, Parry S, / et al.: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. / Clin Cancer Res 2005, 11: 5175鈥?180. CrossRef
  13. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, / et al.: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12鈥?1. / Br J Surg 1994, 81: 1512鈥?515. CrossRef
  14. Nicoletto MO, Donach M, De NA, Artioli G, Banna G, Monfardini S: BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. / Cancer Treat Rev 2001, 27: 295鈥?04. CrossRef
  15. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, / et al.: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. / Lancet 1998, 351: 316鈥?21. CrossRef
  16. Eccles D, Simmonds P, Goddard J, Coultas M, Hodgson S, Lalloo F, / et al.: Familial breast cancer: An investigation into the outcome of treatment for early stage disease. / Familial Cancer 2001, 1: 72. CrossRef
  17. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. / J Clin Oncol 1998, 16: 397鈥?04.
  18. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, / et al.: Familial invasive breast cancers: worse outcome related to BRCA1 mutations. / J Clin Oncol 2000, 18: 4053鈥?059.
  19. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. / Cell 2002, 108: 171鈥?82. CrossRef
  20. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, / et al.: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. / Nat Genet 2006, 38: 1239鈥?241. CrossRef
  21. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, / et al.: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. / Cancer Res 2003, 63: 6221鈥?228.
  22. Eccles DM, Simmonds P: Clinical Management in Hereditary Breast Cancer. / Cancer & Chemotherapy Reviews 2006, 1: 63鈥?9.
  23. POSH study website [http://www.som.soton.ac.uk/research/cancersciences/Research_Groups/Cancer_genetics/POSH/default.htm]
  24. Emery J, Walton R, Murphy M, Austoker J, Yudkin P, Chapman C, / et al.: Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. / BMJ 2000, 321: 28鈥?2. CrossRef
  25. Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. / Am J Hum Genet 1991, 48: 232鈥?42.
  26. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, / et al.: Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. / J Med Genet 2003, 40: 807鈥?14. CrossRef
  27. Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL: Application of breast cancer risk prediction models in clinical practice. / J Clin Oncol 2003, 21: 593鈥?01. CrossRef
  28. Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R: Evaluation of models to predict BRCA germline mutations. / Br J Cancer 2006, 95: 914鈥?20. CrossRef
  29. Moses LE: Measuring effects without randomized trials? Options, problems, challenges. / Med Care 1995, 33: AS8鈥?4.
  30. Eccles DM, Pichert G: Familial non-BRCA1/BRCA2-associated breast cancer. / Lancet Oncol 2005, 6: 705鈥?11. CrossRef
  31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/160/prepub
  
• 作者单位：Diana Eccles (1)
  Sue Gerty (1)
  Peter Simmonds (1)
  Victoria Hammond (1)
  Sarah Ennis (1)
  Douglas G Altman (2)
  
  1. Somers Cancer Sciences Building Mail Point 824, Southampton University Hospitals NHS Trust, Tremona Road, SO16 6YA, Southampton, UK
  2. Centre for Statistics in Medicine, Wolfson College Annexe, Linton Road, OX2 6UD, Oxford, UK
  
• ISSN：1471-2407

文摘

Background Young women presenting with breast cancer are more likely to have a genetic predisposition to the disease than breast cancer patients in general. A genetic predisposition is known to increase the risk of new primary breast (and other) cancers. It is unclear from the literature whether genetic status should be taken into consideration when planning adjuvant treatment in a young woman presenting with a first primary breast cancer. The primary aim of the POSH study is to establish whether genetic status influences the prognosis of primary breast cancer independently of known prognostic factors. Methods/design The study is a prospective cohort study recruiting 3,000 women aged 40 years or younger at breast cancer diagnosis; the recruiting period covers 1st June 2001 to 31st December 2007. Written informed consent is obtained at study entry. Family history and known epidemiological risk data are collected by questionnaire. Clinical information about diagnosis, treatment and clinical course is collected and blood is stored. Follow up data are collected annually after the first year. An additional recruitment category includes women aged 41 to 50 years who are found to be BRCA1 or BRCA2 gene carriers and were diagnosed with their first breast cancer during the study recruiting period. Discussion Power estimates were based on 10% of the cohort carrying a BRCA1 gene mutation. Preliminary BRCA1 and BRCA2 mutation analysis in a pilot set of study participants confirms we should have 97% power to detect a difference of 10% in event rates between gene carriers and sporadic young onset cases. Most of the recruited patients (>80%) receive an anthracycline containing adjuvant chemotherapy regimen making planned analyses more straightforward.